BLTE Stock Summary and Trading Ideas (Belite Bio - American Depositary Shares | NASDAQ:BLTE)

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Belite Bio - American Depositary Shares trades on the NASDAQ stock market under the symbol BLTE.

As of March 2, 2026, BLTE stock price declined to $177.58 with 398,665 million shares trading.

BLTE has a beta of 0.76, meaning it tends to be less sensitive to market movements. BLTE has a correlation of 0.10 to the broad based SPY ETF.

BLTE has a market cap of $6.66 billion. This is considered a Mid Cap stock.

In the last 3 years, BLTE traded as high as $200.00 and as low as $11.00.

The top ETF exchange traded funds that BLTE belongs to (by Net Assets): SPEM, ONEQ, GXC, APIE.

BLTE has outperformed the market in the last year with a price return of +204.8% while the SPY ETF gained +18.6%. BLTE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +37.0% and +1.3%, respectively, while the SPY returned +1.3% and +0.7%, respectively.

BLTE support price is $183.20 and resistance is $197.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLTE shares will trade within this expected range on the day.